Go Back to Match Results for ""
An Open-label Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Study Overview
The purpose of this study is to see if Daratumumab is useful for treating pediatric (subjects aged >=1 to 18 years) and young adult patients (aged 18 to 30 years) with acute lymphoblastic leukemia or lymphoblastic lymphoma.
Study Description
The purpose of this study is to see if Daratumumab is useful for treating pediatric (subjects aged >=1 to 18 years) and young adult patients (aged 18 to 30 years) with acute lymphoblastic leukemia or lymphoblastic lymphoma.
Additional Information
Participants will be compensated for their participation.
- IRB Number: 1806200214 (PHO-JANSSEN-AALL2005)
- Research Study Identifier: TX9370
- Principal Investigator: Batra Sandeep, MD
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required
